Sort by
Refine Your Search
-
liquid biopsy technologies. The technology has been validated on 65 lung cancer and 100+ prostate cancer clinical samples, achieving 90–97% sensitivity. Three patent families protect the core technology
Searches related to multi core
Enter an email to receive alerts for multi-core positions